Psilocybin
Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy
The article Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy was originally published on Microdose.
In big news for access to mental…
The article Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy was originally published on Microdose.
In big news for access to mental health treatments, Alberta has become the first Canadian province to regulate the use of psychedelics for therapy treatment.
On Wednesday, the province announced amendments to the Mental Health Services Protection Act, including changes to rules around opioids prescriptions for people with addiction and the amendments to psychedelic use. The province plans to regulate the use of psychedelics, including psilocybin, psilocin, MDMA, LSD, mescaline, DMT, 5 methoxy DMT, and ketamine, to treat psychiatric disorders. The regulations for psychedelics will come into effect on Jan. 16, 2023.
“Some of the strongest supporters are among first responders and veterans who suffer from high rates of PTSD and other mental health conditions,” said Mike Ellis, associate minister of mental health and addictions. “As a former police officer myself, I want to ensure that if there are promising practices to make life better for people with these conditions that we are supporting them in a professional way.”
As reported by the CBC, Alberta health officials said they are laying out a regulatory groundwork in the province. Alberta’s new regulations would require medical directors to apply for a license before treating patients with psychedelics for mental health disorders. A psychiatrist would have to oversee any treatment, according to the regulations taking effect in January 2023. Health professionals could not charge money for the drugs, and a qualified professional must only give patients the drug at a medical facility – unless the person is in palliative care.
This is an important step forward in not only providing access to treatments for patients in need, but in de-stigmatizing and normalizing psychedelic medicine.
See the full press conference below.
mescaline psilocybin mdma lsd ketamine dmt psychedelic therapy ptsd-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?